about
TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathwayCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsDelayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke modelsOlomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismR-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repairImatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.Enhancement of Peripheral Nerve Regrowth by the Purine Nucleoside Analog and Cell Cycle Inhibitor, Roscovitine.Targeting low molecular weight cyclin E (LMW-E) in breast cancer.Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in miceCyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.Targeted therapy in head and neck cancer.P/Q-type calcium channel modulators.ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistancePolyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells.Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells.A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer.Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model.A Simple Isomerization of the Purine Scaffold of a Kinase Inhibitor, Roscovitine, Affords a Four- to Seven-Fold Enhancement of Its Affinity for Four CDKs. Could This Be Traced Back to Conjugation-Induced Stiffenings/Loosenings of Rotational Barriers?
P2860
Q24337162-C69255B1-4997-4CB3-BB36-A2FBCA872C15Q27670943-AC9C6A11-538D-4D5F-BEC1-D94C82EE55F1Q28475093-A001CB0E-0267-4136-BDD3-394CC68E51DFQ28534229-3B67CEC2-CD79-4EAE-BD79-4F3F15283851Q33864755-6CBDFD9C-5447-4566-8D51-351916FBEF0DQ34489708-277480D8-506B-458A-9C74-7C591A89C318Q34555921-3A6FF2EB-2AA4-452F-B606-ED2C36D63E13Q34954019-D459614B-54CF-4E7D-9574-4EC5C1A67968Q35574807-75DF8DAC-2D25-4258-BD74-F0B4605ABB52Q35995697-DF1131CA-F5CA-4E7F-B217-365B20EC8A7FQ36709312-1075EC6A-9777-48E4-886C-EE588B4C10BEQ37343521-C8C2D862-1F70-4660-A896-65E60E6FC02EQ37373562-633E7920-D365-48E3-B6F1-4D09EDD06F63Q37585018-2AC130FC-6E91-47AE-A62D-593A6BBD305CQ37798827-5991D8D4-2F4E-4161-B363-A09E5762DFF0Q37988981-CA945967-535D-4431-A1C7-C77300D9494FQ38016449-A9B59265-3106-4EBC-9798-71A4E4C6F606Q38752310-92DC5D18-0148-4BF1-9D5B-AC3AE245D42FQ39496558-C0645F92-25F2-45B6-9EBE-09AB2ABBDF9FQ39555976-23F32D9D-7BDD-459B-98ED-DDB705E11922Q39572637-B4D5B833-2D61-4582-B481-91F2B4E9BCF3Q39610270-ABCFDCC8-D191-4BB7-9450-B568FDD6B09CQ42099233-51CDC772-178D-49EC-8AC7-FB70C61CD670Q48728908-8FF3D3C9-79C9-452C-8BCC-F69983814DF3Q53818047-701D72EE-930D-400D-8505-7CF156F44161Q55059946-6CA57E82-6E1C-4CD1-A528-470D32AAFF0CQ58736257-B19CD3DD-3E5E-494D-8D64-97D16312A4EB
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Seliciclib in malignancies.
@en
Seliciclib in malignancies.
@nl
type
label
Seliciclib in malignancies.
@en
Seliciclib in malignancies.
@nl
prefLabel
Seliciclib in malignancies.
@en
Seliciclib in malignancies.
@nl
P2860
P1476
Seliciclib in malignancies.
@en
P2093
Ibrahim T Aldoss
Tsewang Tashi
P2860
P304
P356
10.1517/13543780903418445
P407
P577
2009-12-01T00:00:00Z